Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

Non-Malignant Blood Disorders

Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Haematologica

Dayagi TW, Willis L, Arnold SD, Boklan J, Cada M, Coates TD, Corriveau-Bourque C, Gamper CJ, Geddis AE, Glader B, Kupfer GM, Nakano TA, Olson TS, Rogers ZR, Shimamura A, Takemoto C, Thompson AA, Williams DA, Dror Y

doi: 10.3324/haematol.2025.300232

Gastrointestinal Cancer

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

Lancet Oncol

Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A, CARES-310 Study Group

doi: 10.1016/S1470-2045(25)00543-1

Lung, Respiratory and Thoracic Cancer

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study

Ann Oncol

Shaw AT, Solomon BJ, Felip E, Bauer TM, Liu G, Goto Y, Wu YL, Soo RA, Mazieres J, Kim DW, Wang IM, Paolini J, Polli A, Rifi N, Toffalorio F, Mok TSK

doi: 10.1016/j.annonc.2026.05.692

Non-Malignant Blood Disorders

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Br J Haematol

Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H

doi: 10.1111/bjh.70531

Leukemia

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Br J Haematol

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M

doi: 10.1111/bjh.70418

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

RECOMMENDED

Breast Cancer

HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer

★ 2 Recommended by Dr Andreas Müller, Faculty Member

★ 2 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

J Clin Oncol

Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, Martins de Aquino Pimentel LC, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Shen Q, Santarpia L, Hamilton E

doi: 10.1200/JCO-25-02600

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Lee J, Kim M, Han HJ, Kim S, Suh HS

doi: 10.1016/j.lungcan.2025.108682

Genitourinary Cancer

First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study

Adv Ther

Ren Z, Liang T, Gu S, Gou H, Peng C, Pan Y, Song T, Su H, Cao K, Liang H, Ying J, Geng Z, Yu W, Zhao H, Bai Y, Hao C, Mao Y, Li W, Wang L, Li D, Wang W, Li N, Malhotra U, Qin S

doi: 10.1007/s12325-026-03578-4

Related content